News Headlines Article

FDA issues new draft guidance on Alzheimer’s drug testing
Modern Healthcare

The Food and Drug Administration issued draft guidance today outlining how drug manufacturers could enroll patients who are in the early stages of Alzheimer’s disease in clinical trials in an effort to urge development of new treatments.

Few new drugs have been developed to treat the symptoms of Alzheimer’s disease. The FDA has approved three new drugs since 1998. During the same timeframe, at least 101 drugs have failed to gain approval, according to a report released in September by the Pharmaceutical Research and Manufacturers of America.